FT Options’s Juno Therapeutics, Inc. JUNO Stock Holding History

FT Options’s Portfolio JUNO Stock Details JUNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	$24K	Buy	+12,300	New	+$419K	0.04%	159
2016 Q4	–	Sell	-40,000	Closed	-$5K	–	429
2016 Q3	$5K	Sell	40,000 -20,000	-33%	-$622K	﹤0.01%	329
2016 Q2	$115K	Buy	+60,000	New	+$2.49M	0.1%	136

Other funds holding JUNO

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

FT Options's JUNO Position: Q3 2017 in Review

FT Options opened a new position in Juno Therapeutics, Inc. (JUNO) in Q3 2017: 1,000 shares worth $45K. The stake represents 0.07% of the portfolio and ranks #127 among its holdings.

210 funds tracked by Wall St. Rank hold JUNO as of Q3 2017.

FT Options held 1,000 shares of Juno Therapeutics, Inc. worth $45K as of Q3 2017.
Juno Therapeutics, Inc. was a new FT Options position in Q3 2017.
Juno Therapeutics, Inc. made up 0.07% of FT Options's portfolio in Q3 2017, its #127 holding.
210 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q3 2017.

Based on FT Options's 13F filing for Q3 2017, filed 13 Nov 2017.